Related Experiment Video
Updated: Sep 8, 2025
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
Apigenin alleviates neuroinflammation in a mouse model of Parkinson's disease
Gul Fatma Yarim1, Filiz Kazak2, Murat Yarim3
1Faculty of Veterinary Medicine, Department of Biochemistry, Ondokuz Mayis University, Atakum, Turkey.
Purpose Of The Study:
The aim of this study is to evaluate the effect of apigenin on inflammatory response in brain tissue in Parkinson's mouse model.
Materials And Methods:
Parkinson's disease model was induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Sixty 8-10-weeks-old male C57BL/6 mice were randomly divided into four groups control, Parkinson, prophylaxis, and treatment. Control (0.9% NaCl 0.5 ml, 10 days, i.p.), Parkinson (25 mg/kg MPTP, 5 days, i.p.), prophylaxis (50 mg/kg apigenin, 5 days + 25 mg/kg MPTP, 5 days, i.p.), and treatment (25 mg/kg MPTP, 5 days + 50 mg/kg apigenin, 5 days). The expressions and protein levels of tumor necrosis factor-alpha (TNF-α), interleukin-1-beta (IL-1β), IL-6, IL-10, and transforming growth factor-beta (TGF-β) were determined using immunohistochemistry and enzyme-linked immunosorbent analysis.
Results:
Apigenin administration attenuated MPTP-induced histopathological changes in brain tissue. Furthermore, apigenin reversed the changes in expressions and concentrations of TNF-α, IL-1β, IL-6, IL-10, and TGF-β.
Conclusion:
This study suggests that apigenin could be used as a neuroprotective option to attenuate neuroinflammation in Parkinson's disease.
Insights
Apigenin reduces brain inflammation in a Parkinson
Area of Science:
- Neuroscience
- Pharmacology
- Immunology
Background:
- Parkinson's disease is a neurodegenerative disorder characterized by progressive loss of dopaminergic neurons.
- Neuroinflammation plays a critical role in the pathogenesis and progression of Parkinson's disease.
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a widely used neurotoxin to induce Parkinsonism in animal models.
Purpose of the Study:
- To investigate the potential neuroprotective effects of apigenin against MPTP-induced neuroinflammation in a mouse model of Parkinson's disease.
- To evaluate the impact of apigenin on the expression of key inflammatory markers in the brain tissue of Parkinsonian mice.
Main Methods:
- A Parkinson's disease mouse model was established using MPTP administration.
- Mice were divided into control, Parkinson's, prophylaxis (apigenin before MPTP), and treatment (apigenin after MPTP) groups.
- Immunohistochemistry and ELISA were employed to measure the levels of TNF-α, IL-1β, IL-6, IL-10, and TGF-β.
Main Results:
- Apigenin administration significantly attenuated MPTP-induced histopathological damage in the brain.
- Apigenin treatment reversed the altered expressions and concentrations of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and anti-inflammatory cytokines (IL-10, TGF-β).
Conclusions:
- Apigenin demonstrates significant neuroprotective properties by mitigating neuroinflammation in the MPTP-induced Parkinson's disease model.
- Apigenin holds promise as a potential therapeutic agent for managing neuroinflammation associated with Parkinson's disease.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:37Neural Regulation